๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sydney
Clinical trial register · Australia

Clinical Trials in Sydney, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Melbourne 32 Westmead 30 Brisbane 28 Clayton 22 Frankston 21
Narrow the registerReset
Recruitment status
Phase
Site location
Melbourne32 Westmead30 Brisbane28 Clayton22 Frankston21
All 78 locations
Target enrolment
to

Trials with a site in Sydney

16 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC
Phase 3
450
Kogarah, Sydney, Frankston
2026-03-23
Recruiting
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
NCT07247110Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1
250
Sydney, Clayton, Melbourne, Nedlands
2025-12-16
Active, closed
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
NCT07216482Hyperlipidemia
Merck Sharp & Dohme LLC
Phase 3
996
Maroubra, Sydney, Taringa, Norwood, Camberwell, Hoppers Crossing
2025-11-11
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1/2
50
Sydney, Brisbane, Parkville
2025-05-26
Recruiting
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694Gastrointestinal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
180
Sydney, Melbourne, Mount Pleasant
2024-11-03
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
St Leonards, Sydney, Brisbane, East Melbourne, Frankston
2023-12-06
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 3
1,109
Kingswood, Sydney, Brisbane, Adelaide, Clayton, Melbourne
2023-10-25
Active, closed
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
NCT05766501HIV Infection
Merck Sharp & Dohme LLC
Phase 3
641
Darlinghurst, Sydney, Brisbane, Melbourne
2023-03-17
Active, closed
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
NCT05631093HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
553
Darlinghurst, Sydney, Brisbane, Melbourne
2023-02-20
Active, closed
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
NCT04776252HIV-1 Infection
Merck Sharp & Dohme LLC
Phase 3
2,000
Darlinghurst, Sydney, Murdock
2021-09-15
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Sydney, Box Hill, Nedlands
2021-04-05
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-australia/city/sydney

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Sydney that also match the filters currently applied.

How many clinical trials are recruiting in Sydney?

7 of the 16 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Sydney), 16 studies
PhaseStudiesRecruitingShare
Phase 312375%
Phase 1/22212.5%
Phase 1116.3%
Phase 2116.3%

Most active sponsors

Lead sponsors with the most studies (Sydney)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC167
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.